Aspire Growth Partners LLC Takes $212,000 Position in Gilead Sciences, Inc. $GILD

Aspire Growth Partners LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,910 shares of the biopharmaceutical company’s stock, valued at approximately $212,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC grew its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the 2nd quarter worth $27,000. Putney Financial Group LLC increased its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors raised its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday, November 10th. Truist Financial initiated coverage on shares of Gilead Sciences in a report on Monday, November 24th. They issued a “buy” rating and a $140.00 price target for the company. Finally, Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $130.65.

Insider Activity

In related news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. The trade was a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 115,146 shares of company stock valued at $14,012,141. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $125.85 on Friday. The firm has a market capitalization of $156.13 billion, a P/E ratio of 25.07, a PEG ratio of 0.81 and a beta of 0.32. The stock has a 50-day simple moving average of $119.87 and a two-hundred day simple moving average of $114.49. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a fifty-two week low of $88.57 and a fifty-two week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the business earned $2.02 earnings per share. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.